TMOD-15. EFFICACY OF THE MDM2 INHIBITOR KRT-232 IN GLIOBLASTOMA PATIENT-DERIVED XENOGRAFT MODELS

Non-genotoxic reactivation of p53 by MDM2 inhibitors represents a promising therapeutic strategy for tumors with wild-type TP53, particularly tumors harboring MDM2 amplification. MDM2 controls p53 levels by targeting it for degradation, while disruption of the MDM2-p53 interaction causes rapid accum...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Vaubel, Rachael, Mladek, Ann, Zhao, Yu, Gupta, Shiv K, Kim, Minjee, Mohammad, Afroz S, Bakken, Katrina, He, Lihong, Hu, Zeng, Burgenske, Danielle M, Carlson, Brett L, Elmquist, William F, Sarkaria, Jann
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Tumor Models
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651455/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.966
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados